Seroprevalence and asymptomatic carriage of Leishmania spp. in Austria, a non-endemic European country  by Poeppl, W. et al.
Seroprevalence and asymptomatic carriage of Leishmania spp. in
Austria, a non-endemic European country
W. Poeppl1,2, H. Herkner3, S. Tobudic1, A. Faas4, H. Auer5, G. Mooseder2, H. Burgmann1 and J. Walochnik5
1) Department of Infectious Diseases and Tropical Medicine, Medical University of Vienna, 2) Department of Dermatology and Tropical Medicine, Military
Hospital Vienna, 3) Department of Emergency Medicine, Medical University of Vienna, 4) Institute for Medical Support, Military Hospital Vienna and
5) Institute of Specific Prophylaxis and Tropical Medicine, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
Abstract
Leishmaniasis is a rare disease in Central Europe and is diagnosed almost exclusively in travellers or migrants coming from tropical or
subtropical countries. We conducted an explorative cross-sectional serological study, using a commercial ELISA, in 1048 healthy Aus-
trian individuals to assess the distribution of specific antibodies against Leishmania spp. in humans in Austria. Overall, 47 individuals
(4.5%) tested positive, and an additional 32 (3.1%) showed borderline results. After 12 months, sera from 42 of the 79 individuals who
had initially tested seropositive/borderline were tested by ELISA a second time: 18 were persistently positive, nine were borderline.
Those whose sera were persistently positive/borderline were then screened for potential carrier status using a commercial oligochro-
matographic PCR test to detect parasite DNA. Four samples were PCR positive and were subjected to a second PCR allowing parasite
identification after DNA sequencing: two samples were identified as Leishmania donovani/infantum complex and Leishmania (Viannia)
guyanensis, respectively. Epidemiological information was obtained with a questionnaire: no correlation was found for the number of hol-
iday trips within the previous 6 months, but a significant risk of exposure to Leishmania spp. was found for travel to the New World,
particularly to the Caribbean. Our data demonstrate that Leishmania spp. seroprevalence in non-endemic countries has been consider-
ably underestimated.
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Introduction
Leishmania species, transmitted by sandflies (Phlebotominae),
are the causative agents of visceral leishmaniasis (VL) and
several different forms of cutaneous leishmaniasis (CL),
depending mainly on the virulence of the respective strain
and on the immune status of the patient [1,2]. VL is a fatal
disease if left without treatment and with the advent of AIDS
an important new risk factor for developing VL has emerged.
Approximately 12 million individuals are currently infected
with Leishmania spp. worldwide, with an estimated 2 million
new cases occurring every year [3]. Major endemic areas are
in the tropics and subtropics; however, several Leishmania
spp. also occur in southern Europe, where the predominant
group is the L. donovani/infantum complex, and thereof
zymodemes MON-1 and MON-24 [4] and genotypes 1 (cor-
responding to MON-1) and 2 (non-MON-1) [5]. Moreover,
L. tropica occurs at least sporadically on the Balkan peninsula
[6]. Reservoir hosts of Leishmania spp. are small mammals
and, particularly in urban areas, dogs.
There has been growing evidence for endemic populations
of sandflies also in Central Europe [7,8], where leishmaniasis
is a rare and not notifiable disease, diagnosed almost exclu-
sively in travellers or migrants. Infections acquired in the Med-
iterranean region usually remain asymptomatic in healthy
adults but can progress seriously in children and in immuno-
compromised individuals. The aim of the present study was to
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assess the prevalence of specific antibodies against Leishmania
spp. in healthy individuals in Austria, a non-endemic country.
Materials and Methods
Subjects and study design
We conducted an explorative national cross-sectional sero-
logical study in healthy Austrian individuals volunteering for
UN missions. The study was approved by the Ethics Commit-
tee of the Austrian Armed Forces. In Austria, both civilians
and members of the armed forces are eligible for military
missions abroad. Before deployment, all volunteers are
required to pass medical examinations at the Military Hospital
Vienna. Routine examinations include physical examinations
and laboratory investigations (complete blood count, blood
chemistry and screening for HIV infection). Serological testing
for Leishmania spp. was added to this routine screening.
In the first part of the study 1048 individuals from all nine
federal states of Austria were investigated, among whom 425
(40.6%) were professional soldiers and 623 (59.4%) civilians.
All participants completed a questionnaire on demographic
characteristics, contact with domestic animals, regular out-
door activities, previous tick bites, previous international mil-
itary operations, and holiday destinations abroad within the
previous 6 months. Subjects were between 18 and 60 years
old (mean 26 years), 1031 (98.4%) being male and 17 (1.6%)
female. Altogether, 395 (37.7%) persons, professional sol-
diers and civilians, declared previous assignments abroad.
None of the subjects was taking immunosuppressive medica-
tion or had an immunosuppressive condition. A commercial
ELISA kit was used for anti-Leishmania antibody screening.
In the second part of the study, all initially seropositive
and borderline subjects were invited for a follow-up after
12 months. Serum samples were again tested by ELISA.
EDTA whole blood was also obtained to test for the pres-
ence of Leishmania DNA in PCR; Leishmania species were
identified using DNA sequencing.
Serology
Anti-Leishmania antibodies were assessed using the RIDA-
SCREEN Leishmania AB ELISA kit (R-Biopharm AG, Darms-
tadt, Germany) according to the manufacturer’s instructions.
This ELISA is for the qualitative detection of antibodies
against Leishmania spp. in human serum and uses a polyvalent
conjugate to detect IgG, IgM and IgA.
Molecular diagnostics
DNA was extracted from EDTA whole blood samples using
the peqGOLD Blood DNA Kit (Peqlab, Erlangen, Germany).
The advantage of this extraction kit is that 1 mL of blood
can be applied, thus the yield of parasite DNA is consider-
ably higher than with standard kits using an initial volume of
200 lL. For the first PCR, the Leishmania OligoC-Test
(Coris BioConcept, Gembloux, Belgium) was used according
to the manufacturer’s instructions. In this PCR, Leishmania
18S ribosomal DNA is amplified, followed by a single one-
step oligochromatographic membrane assay using colloidal
gold particles and specific oligonucleotide probes. According
to the manufacturer, the assay detects all Leishmania species,
including representatives of the Viannia subgroup.
All samples that were positive in the oligochromatographic
PCR were retested by a universal Leishmania PCR [9] ampli-
fying a 300–350 bp fragment including the first internal tran-
scribed spacer (ITS1). Double-distilled molecular grade water
(Sigma-Aldrich, Vienna, Austria) was used as a negative con-
trol. Amplicons were visualized in a 2% agarose gel by stain-
ing with ethidium bromide, and the amplified products were
excised from the gel and purified using the Gel Band Purifica-
tion Kit (GE Healthcare, Zipf, Austria). All amplicons were
sequenced by direct sequencing using the BigDye sequenc-
ing kit and an automatic 310 ABI PRISM sequencer (PE
Applied Biosystems, Darmstadt, Germany). Sequences were
obtained from both strands and sequence data were pro-
cessed with the GeneDoc sequence editor (http://
www.nrbsc.org/gfx/genedoc/) in order to obtain consensus
sequences. The sequences were compared with published
sequences from the GenBank by BLAST search.
Statistics
As no estimates for prevalence of Leishmania spp. in non-
endemic regions were available, no formal sample size was
calculated. We used a convenience sample of approximately
1000 individuals based on available resources. With this sam-
ple we could expect a meaningful 95% confidence interval
(CI) from 0.2 to 1.2%. Data are presented as mean ± stan-
dard deviation; categorical data are presented as absolute
and relative frequency. For hypothesis testing to describe dif-
ferences between negative, borderline and positive individu-
als we used the Mann–Whitney U-test, chi-squared or
Fisher’s exact test as appropriate. We described Leishmania
spp. prevalence as relative frequencies with exact 95% CIs.
We also calculated a population estimate for the prevalence
of Leishmania spp. infection in men using direct standardiza-
tion with the national census in Austria 2009 (http://
www.statistik.at). To identify risk factors for an individual
testing Leishmania spp. non-negative (i.e. positive or border-
line) we calculated odds ratios with exact 95% CIs using
logistic regression models. For data management and analysis
we used MS Excel 2011, GRAPHPAD PRISM 5 and STATA 11 for
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Mac (College Station, Texas, USA). Generally a two-sided
p-value <0.05 was considered statistically significant.
Results
Initial screening and risk factors
In total, 47 of 1048 individuals (4.5%; 95% CI, 3.3–5.9) were
positive in the initial serological screening, an additional 32
(3.1%; 95% CI, 2.1–4.3) samples being borderline. On the
basis of the age distribution in Austria, we calculated an age-
adjusted prevalence rate of 5.3% (95% CI, 1.4–14.1) for being
positive and 1.6% (95% CI, 0.5–8.5) for being borderline.
None of the individuals who tested positive had a medical
history of visceral or cutaneous leishmaniasis. All seroposi-
tive individuals were male; none of the 17 female individuals
tested showed antibodies against Leishmania spp. Seropositiv-
ity did not increase with age. The odds ratios for the vari-
ables surveyed to identify risk factors for Leishmania spp.
seropositivity are outlined in Fig. 1. Of the positive individu-
als, 48.9% were professional soldiers and 51.1% were civil-
ians; within the borderline group the percentages were
37.5% and 62.5%, respectively. Only 34% of the individuals
with positive serology had been on a mission abroad. Thus,
no significant association was identified for professional sol-
diers (OR, 1.18; 95% CI, 0.74–1.87) or for previous military
missions abroad (OR, 0.75; 95% CI, 0.46–1.23). Concerning
holiday trips abroad within the previous 6 months, no corre-
lation was found for the number of trips, but a significant
risk of exposure to Leishmania spp. was found for travel to
the New World (OR, 2.76; 95% CI, 1.11–6.89), particularly
the Caribbean (OR, 25.14; 95% CI, 2.25–280.40). Interest-
ingly, one of the seropositive subjects had never travelled
abroad and another had travelled only to Norway.
Concerning differences between the federal states of Austria,
seropositivity was highest in individuals living in the south-
eastern parts of Lower Austria (8.3%), in the Burgenland
(8.3%) and in Vienna (6%), together representing the low
eastern part of Austria, and lowest in the mountainous wes-
tern parts of Lower Austria (0.9%). However, these differ-
ences were not statistically significant. Similarly, no
association was found for pet ownership (OR, 1.03; 95% CI,
0.65–1.63), regular outdoor activities (OR, 1.22; 95% CI,
0.67–2.22) or tick-bites (yes/no) more than 3 years before
Leishmania spp. screening (OR, 0.71; 95% CI, 0.44–1.13).
However, the risk of being seropositive was significantly
higher for individuals reporting more than one tick bite
annually (OR, 2.08; 95% CI, 1.12–3.85) or tick bites within
the 3 months before serological testing (OR, 2.58; 95% CI,
1.32–5.01).
Follow-up
Twelve months after the initial screening, 42 of the 79 origi-
nally positive or borderline subjects were retested by ELISA.
Of these, 18 were still positive and nine were borderline.
With three exceptions, antibody levels were considerably
lower in the second testing: ELISA antibody indices were
mostly only half as high as 1 year before. All 27 (100%) sub-
jects with persistently positive or borderline results reported
regular outdoor activity, in contrast to 21% in the initial
study cohort.
In the oligochromatographic PCR, four (14.8%) of these
27 individuals (three seropositive, one borderline) were also
positive for Leishmania DNA. None of the four had been
abroad during the previous 6 months; however, all had pets.
Samples from two of the four were also positive in the sec-
ond PCR; these were identified by DNA sequencing as Leish-
mania donovani/infantum complex and Leishmania (Viannia)
guyanensis complex, respectively. These two individuals were
22 and 34 years old, and both were professional soldiers.
Interestingly, the 34-year-old man with an asymptomatic L.
(V.) guyanensis complex infection had history of travel to vari-
ous Mediterranean countries and to New York, but had
never travelled to Central or South America [10].
High seropositivity did not necessarily correlate with PCR
positivity. The two individuals who tested positive in both
PCRs had ELISA antibody indices of 1.6 and 1.4, respectively
(cut-off 0.9), whereas the two individuals showing the highest
ELISA values after 12 months (3.4 and 2.6, respectively)
tested PCR negative. In the two individuals who tested posi-
tive in both PCRs, antibodies had not declined; one showed
exactly the same level after a year and in the other the index
had declined by only 0.1.
Discussion
Data on human exposure to Leishmania spp. are lacking in
European countries with no endemicity. The current investi-
gation in 1048 individuals is the first study on Leishmania spp.
seroprevalence in Austria.
Seropositivity in asymptomatic individuals
At 4.5%, Leishmania spp. seroprevalence was unexpectedly
high, considering that Austria is a non-endemic country.
However, the majority of Austrians regularly travel to the
Mediterranean, where leishmaniasis is endemic. Autochtho-
nous transmission may not be entirely excluded (see below),
but the high level of seropositivity in healthy individuals
demonstrates that the number of imported Leishmania spp.
infections in Central Europe might have been seriously
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underestimated – and corroborates once more that the
majority of Leishmania spp. infections progress subclinically,
also known to be the case in endemic areas [1,11].
Nevertheless, asymptomatic infections are of medical rel-
evance. Firstly, Leishmania spp. parasites may persist and
infected individuals may develop serious leishmaniasis when
acquiring immunodeficiency. Secondly, carriers may function
as reservoir hosts [3,4,12]. Although the introduction of
active antiretroviral treatment has changed the outcome of
AIDS-associated leishmaniasis, concordant HIV infection and
VL still carry high rates of relapse and mortality [13]. In
addition, immune-modifying agents, such as TNF-alpha inhibi-
tors, increasingly used to treat inflammatory diseases, may
cause a more severe progression or a relapse of leishmaniasis
FIG. 1. Forest plot of risk factors for an indi-
vidual to test Leishmania spp. non-negative (i.e.
positive or borderline) in the initial serological
screening. Dots represent odds ratios, hori-
zontal lines represent 95% CIs. Postal codes:
1 = Vienna, 2 = Lower Austria (East of
Vienna), 3 = Lower Austria (West of Vienna),
4 = Upper Austria, 5 = Salzburg and Eastern
Upper Austria, 6 = Tyrol and Vorarlberg
(without Eastern Tyrol), 7 = Burgenland,
8 = Styria, 9 = Carinthia and Eastern Tyrol.
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[14]. Current recommendations do not require Leishmania
spp. infection to be considered before anti-TNF-a therapy
or transplantation. Also, regulations for blood transfusions
might need reconsideration, particularly when children or
immunocompromised individuals are involved [15,16].
Antibody persistence
Almost 50% of the initially seropositive individuals retested
after 12 months were still seropositive. It is known that
after acute VL specific antibodies can be detected for many
years, probably mainly owing to persistence of the parasites
[17]. A further finding in the present study was that four
individuals were PCR positive when followed-up after a
year, suggesting that Leishmania spp. parasites were still
present. This correlates with the observation that in these
individuals antibody indices remained constant, whereas in
most other individuals indices had significantly decreased at
follow-up. Interestingly, in three other individuals the anti-
body indices had risen, but as they were all negative in PCR
it remains unknown whether this was a true rise or
whether they had acquired a re-infection during these
12 months.
Transmission in Central Europe?
Although, with two exceptions, all seropositive individuals
had at least once in their lifetime travelled to an endemic
area, more than half had not travelled abroad within the
6 months before screening. Once infected with Leishmania
spp., an individual might remain positive for a very long
time; however, this is certainly not true for all persons.
Also in our study approximately 50% of the individuals posi-
tive in the first testing were negative at follow-up 1 year
later.
In Europe, the most important reservoir hosts are dogs
and in some Mediterranean areas 50% of the stray dogs
are infected [18]. Many of these animals have been brought
to Central Europe by compassionate tourists; moreover,
tourists increasingly take their own dogs with them when
they go abroad on holiday. An estimated 20 000 dogs
infected with Leishmania spp. are living in Germany at pres-
ent [7]. In Austria, up to 50% of diseased imported dogs
are infected with Leishmania spp. [19,20] and as dogs are
assumed to remain reservoirs even after successful therapy
[21], there is surely a reservoir of Leishmania spp. infection.
In 2009 it became known that sandflies occur in Austria,
but until now only Phlebotomus mascittii has been found [22]
and its vector capability is still a matter of debate. Two
human cases of leishmaniasis with assumed autochthonous
infection in Austria are documented in the literature
[23,24].
In the present study there was an interesting correlation
between seropositivity and multiple or very recent tick bites.
Ticks are not considered competent vectors for Leishmania
spp., but they certainly take up the parasites regularly in
endemic areas. There are no data on whether they can pass
on at least parts of the parasites that might elicit an antibody
reaction; however, a link between seropositivity and tick
bites has been found also in dogs [25] and Leishmania DNA
has been detected in tick eggs and larvae [26].
Limitations of the study
Firstly, the population sample almost exclusively comprised
healthy male adults, thus the results cannot be generalized to
the overall Austrian population. Particularly in the case of
L. infantum, children and immunosuppressed individuals are
known to be more likely to develop a clinical manifestation
after infection.
Secondly, the study included professional soldiers as well as
civilians. However, as we found no significant differences in
seropositivity rates between these two groups and as almost
all representatives from both groups had already travelled to
endemic areas – as can be assumed for almost the entire Aus-
trian population – we do not consider this difference relevant.
Lastly, it is well known that in many cases of cutaneous
infections with Leishmania spp. there is no detectable sero-
logical response, even in symptomatic patients. Thus, possible
exposure to dermatotropic Leishmania strains was presum-
ably not detected in the present study.
Conclusions
Overall, our findings demonstrate that both seropositivity
and carriage of Leishmania spp. in non-endemic countries
have been considerably underestimated – and this may
necessitate rethinking of clinical routine.
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